Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Flexjak 11mg Tablet ER

Prescription Icon
Prescription Required

Marketer

Abbott Healthcare Private Limited

Salt Composition

Tofacitinib (11mg)

Overview Flexjak 11mg Tablet ER

Artiva 11mg Extended-Release Tablets are indicated for managing moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. This medication alleviates joint pain, tenderness, and swelling by suppressing inflammation, and also helps retard the progression of bone and joint deterioration. Artiva 11mg ER may be administered alone or in conjunction with other therapies. These tablets can be ingested with or without food, ideally at the same time daily. Dosage is individualized based on your medical history and other medications. Always adhere to your physician's prescribed regimen; abrupt cessation should only occur under their guidance as it could exacerbate your condition. Commonly reported adverse effects include upper respiratory infections, headache, diarrhea, and nasopharyngitis. Less frequent, but potentially serious, side effects such as blood clots and gastrointestinal perforations necessitate immediate medical attention. Report any concerns regarding side effects to your doctor. Pre-treatment blood work may be necessary, and initiation of therapy is contraindicated in the presence of any infection. Prior to commencing treatment, discuss your medical history with your physician, including any history of tuberculosis, herpes zoster, hepatic or renal impairment, hepatitis B or C, or thromboembolic events. Artiva 11mg ER increases susceptibility to infection; avoid contact with individuals exhibiting contagious illnesses (e.g., varicella, rubeola, influenza). This medication is unsuitable for patients under 18 years of age and should not be used during pregnancy or lactation except when deemed medically necessary by your doctor. Regular monitoring by your physician may be required.

Uses of Flexjak 11mg Tablet ER

Managing rheumatoid, psoriatic, and ankylosing spondylitis, plus ulcerative colitis.

Major Benefits of Flexjak 11mg Tablet ER:

Administer Flexjak 11mg Extended-Release Tablets precisely as directed by your physician. Ingest the tablet whole; avoid chewing, crushing, or fracturing. This medication can be consumed with or without food, however, consistent daily timing is recommended.

Common Side effects of Flexjak 11mg Tablet ER:

  • Upper respiratory tract infection
  • Headache
  • Diarrhea
  • Nasopharyngitis (inflammation of the throat and nasal passages)

How to use Flexjak 11mg Tablet ER:

Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Flexjak 11mg Extended-Release Tablets can be consumed with or without food, though consistent timing is recommended.

How Flexjak 11mg Tablet ER works:

Extended-release Flexjak 11mg tablets are Janus kinase inhibitors that suppress Janus kinase enzyme activity. This reduces immune system response and inflammation characteristic of rheumatic conditions and ulcerative colitis.

SAFETY ADVICE

AlcoholAlcoholSAFE

There are no reported adverse reactions from concurrent use of Flexjak 11mg Tablet ER and alcohol.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Flexjak 11mg tablets may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the potential benefits against possible risks prior to prescription. Physician consultation is advised.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Flexjak 11mg tablets are likely unsuitable for use while breastfeeding. Available human data indicate potential transfer to breast milk, posing a possible risk to the infant.

DrivingDrivingSAFE

Driving ability is typically unaffected by Flexjak 11mg Extended-Release Tablets.

KidneyKidneyCAUTION

Extended-release Flexjak 11mg tablets require careful administration in individuals with advanced kidney impairment. Dosage modification of Flexjak 11mg extended-release tablets may be necessary. Physician consultation is recommended.

LiverLiverCAUTION

The extended-release Flexjak 11mg tablet requires careful administration for individuals with significant hepatic impairment. Dosage modification of Flexjak 11mg Tablet ER might be necessary. Physician consultation is advised.

What if you forget to take Flexjak 11mg Tablet ER :

Should you forget a Flexjak 11mg Extended-Release Tablet dose, administer it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Flexjak 11mg Tablet ER

LabelValue
Type of Compound Pyrrolopyrimidine-based compound
Addictive None.
Treatment Category Medication for pain relief
Mechanism of Action JAK inhibitors

FAQs on Flexjak 11mg Tablet ER

Prior to commencing treatment with Flexjak 11mg Extended-Release Tablets, disclose any existing liver conditions to your physician. This precaution is necessary as Flexjak 11mg Extended-Release Tablets may elevate liver enzyme levels in certain individuals. Consequently, assessment of your liver function is required before initiating Flexjak 11mg Extended-Release Tablet therapy. While use is permissible in patients with mild to moderate hepatic impairment, Flexjak 11mg Extended-Release Tablets are contraindicated in patients with severe hepatic dysfunction.
Prolonged use of Flexjak 11mg Extended-Release tablets can elevate the likelihood of lymphoma and other cancers, including skin cancers, due to its impact on the immune system. Therefore, disclose any history of cancer to your physician.
Extended-release Flexjak 11mg tablets are indicated for patients exhibiting moderate to severe rheumatoid arthritis, a joint inflammatory condition. This medication is prescribed when prior treatments proved ineffective or unsuitable. Alternatively, it may be employed earlier in the treatment course if initial medications fail to provide adequate relief. Flexjak 11mg may be administered as a monotherapy or in conjunction with other drugs, including methotrexate.
The onset of noticeable improvement with Flexjak 11mg Extended-Release Tablets typically occurs within two to eight weeks, while achieving peak therapeutic benefit may require three to six months.
Prior to commencing or during treatment with Flexjak 11mg Tablet ER, blood work may be required. These tests assess for anemia (low red blood cell count), neutropenia or lymphopenia (low white blood cell count), elevated cholesterol (high blood fat), and increased liver enzyme levels. This monitoring helps determine if Flexjak 11mg Tablet ER is causing adverse effects. Furthermore, pre-treatment tuberculosis testing may be recommended by your physician, as Flexjak 11mg Tablet ER use could potentially exacerbate a pre-existing infection.
Flexjak 11mg Extended-Release tablets modulate the immune system. This can compromise the body's defense against infection, raising the likelihood of severe infections, such as tuberculosis. The risk also encompasses systemic fungal, bacterial, or viral infections. Such infections may be life-threatening and fatal; therefore, inpatient treatment is recommended.
Combining tocilizumab and Flexjak 11mg Tablet ER is inadvisable. Flexjak 11mg Tablet ER's impact on the immune system necessitates avoiding concurrent use with other immunosuppressants. This combination elevates infection risk and may cause additional adverse effects.
Flexjak 11mg Tablet ER
328
MRP 400
18% off